Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Inhaled Triple Therapies on Small Airway in Biomass-Related COPD and Chronic Bronchitis
NCT06571942Phase 4Recruiting
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
- Start
- Nov 2023
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 4 trial of fluticasone furoate + umeclidinium bromide + vilanterol trifenatate, beclometasone dipropionate/formoterol fumarate/glycopyrronium, Breztri Aerosphere in chronic obstructive pulmonary disease (COPD), chronic bronchitis (CB), sponsored by Instituto Nacional de Enfermedades Respiratorias. Started Nov 2023; status: recruiting.
02
Drugs
fluticasone furoate + umeclidinium bromide + vilanterol trifenatatebeclometasone dipropionate/formoterol fumarate/glycopyrroniumBreztri Aerosphere
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on NCT06571942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06571942.